3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
9
Triple Negative Breast Neoplasms
3
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Leukemia
2
Carcinoma, Non-Small-Cell Lung
2
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Non-small Cell Lung Cancer Metastatic
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Meningioma
1
Melanoma
1
Lymphoma
1
Fallopian Tube Neoplasms
1
Exanthema
1
Endometrial Neoplasms
1
Disease Progression
1
Diarrhea
1
Chondrosarcoma
1
Carcinoma, Squamous Cell
1
CCCA Assessed by Ki67 Drop Below <2.7% From Baseline
1
Advanced Gastric Cancer
1
Advanced Cancer
1
Advanced Breast Cancer
1
Interventions
Loperamide
4
Irinotecan
4
Probiotics
3
Fecal Microbiota Transplantation
3
Octreotide
2
Leucovorin
2
Fluorouracil
2
Calcium Aluminosilicate
2
telotristat ethyl
1
shosaiko-to
1
maltodextrin
1
ceterizine hydrochloride
1
capivasertib
1
cabazitaxel
1
bile acid binding proteins
1
XRP6258
1
Theophylline
1
Temozolomide
1
Surveys and Questionnaires
1
Sulfasalazine
1
Sugars
1
Standard of Care
1
Raloxifene Hydrochloride
1
Radiation
1
Prednisone
1
Oxaliplatin
1
Long-Term Synaptic Depression
1
Injections
1
Granulocyte Colony-Stimulating Factor
1
Fulvestrant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Diarrhea
×
capivasertib
×
Clear all
NCT07426822
2026-02-24
SAFE-CAP
Yale University
Phase 2
Not yet recruiting
108 enrolled